©The Author(s) 2016.
World J Gastroenterol. Nov 14, 2016; 22(42): 9300-9313
Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9300
Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9300
Table 4 Prediction of response to anti-tumor necrosis factor therapy - possible biomarkers
| Material/method | Predictor for response | Disease | Ref. |
| Intestinal biopsies | IL1B (upregulated in non-responders) | CD | [54] |
| IL17A (upregulated in non-responders) | |||
| Intestinal biopsies | IL13RA2 | CD and UC | [16] |
| PTGS2 | |||
| WNT5A | |||
| Blood | high CAI | UC | [17] |
| negative ANCA | |||
| IL23R | |||
| Blood | High API | CD | [83] |
| Blood | C-reactive protein | CD and UC | [84] |
| Intestinal biopsies | TNFRSF11B (osteoprotegerin) | UC | [85] |
| STC1 (stanniocalcin-1) | |||
| PTGS2 (prostaglandin-endoperoxide synthase 2) | |||
| IL13Ralpha2 (IL13R alpha 2) | |||
| IL11 (IL-11) | |||
| SPECT | High apoptosis rate | CD | [80] |
| Endoscopic molecular imaging | High mucosal mTNF expression in vivo | CD | [18] |
- Citation: Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 2016; 22(42): 9300-9313
- URL: https://www.wjgnet.com/1007-9327/full/v22/i42/9300.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i42.9300